Sage Will get $Three Billion Endorsement of Its Melancholy Medicine From Biogen

Shaken by a government advisory panel’s poor review of its experimental treatment for Alzheimer’s disease, Biogen announced a team-up Friday with Sage Therapeutics. Biogen has committed up to $3.1 billion to the development and marketing of two drugs that Sage is developing for depression and neurological disorders.

If successful, the drugs would shore up Biogen’s position in treating the nervous system—a market where its prospects are clouded by the weak clinical trials of its Alzheimer’s drug aducanumab and by the arrival…

Read More: | For More Business Articles | Visit Our Facebook & Twitter @kbcchanneltv | Making The Invisible, Visible

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker
%d bloggers like this: